DE1252330T1 - Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie - Google Patents

Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie

Info

Publication number
DE1252330T1
DE1252330T1 DE1252330T DE00981103T DE1252330T1 DE 1252330 T1 DE1252330 T1 DE 1252330T1 DE 1252330 T DE1252330 T DE 1252330T DE 00981103 T DE00981103 T DE 00981103T DE 1252330 T1 DE1252330 T1 DE 1252330T1
Authority
DE
Germany
Prior art keywords
epilepsy
prognosing
loci
mutations
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1252330T
Other languages
English (en)
Inventor
Guy A Rouleau
Ronald G Lafreniere
Daniel Rochefort
Patrick Cossette
David Ragsdale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22608112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE1252330(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by McGill University filed Critical McGill University
Publication of DE1252330T1 publication Critical patent/DE1252330T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
DE1252330T 1999-11-26 2000-11-24 Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie Pending DE1252330T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16762399P 1999-11-26 1999-11-26
PCT/CA2000/001404 WO2001038564A2 (en) 1999-11-26 2000-11-24 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy

Publications (1)

Publication Number Publication Date
DE1252330T1 true DE1252330T1 (de) 2003-11-27

Family

ID=22608112

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1252330T Pending DE1252330T1 (de) 1999-11-26 2000-11-24 Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie

Country Status (7)

Country Link
US (5) US7485449B2 (de)
EP (2) EP2112234A3 (de)
JP (2) JP4048053B2 (de)
AU (5) AU1846501A (de)
CA (1) CA2394229C (de)
DE (1) DE1252330T1 (de)
WO (1) WO2001038564A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202499B2 (en) * 1998-12-10 2010-11-18 Bionomics Limited Mutations in ion channels
CA2394229C (en) 1999-11-26 2010-04-13 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US20020076780A1 (en) * 2000-08-16 2002-06-20 Turner C. Alexander Novel human ion channel proteins and polynucleotides encoding the same
AUPR220300A0 (en) * 2000-12-20 2001-01-25 Bionomics Limited New epilepsy gene
AU2002216826B2 (en) * 2000-12-20 2007-07-12 Bionomics Limited Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
AUPR492201A0 (en) * 2001-05-10 2001-06-07 Bionomics Limited Novel mutation
JP2005501536A (ja) 2001-07-18 2005-01-20 バイオノミックス リミテッド イオンチャネルにおける変異
US7709225B2 (en) 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US20060088827A1 (en) * 2002-01-17 2006-04-27 Rainer Hipfel Diagnostic and therapeutic use of a voltage-gated ion channel scn2a for neurodegenerative diseases
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
WO2003072751A2 (en) * 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
JP2007518422A (ja) * 2004-01-21 2007-07-12 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 変異体ナトリウムチャンネルＮａν１．７およびそれに関連する方法
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US20100088778A1 (en) * 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
US7766942B2 (en) * 2006-08-31 2010-08-03 Warsaw Orthopedic, Inc. Polymer rods for spinal applications
CL2007002950A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer
WO2009006793A1 (en) * 2007-07-06 2009-01-15 The Chinese University Of Hong Kong Polymorphisms of scn2a associated with resistance to antiepileptic drugs and use thereof
RU2011119626A (ru) 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
PT2585596T (pt) 2010-06-23 2021-03-23 Curna Inc Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna
US8919356B2 (en) 2010-12-14 2014-12-30 Whirlpool Corporation Ozone generation module
EP2686340A2 (de) 2011-03-16 2014-01-22 Amgen Inc. Hochwirksame und selektive inhibitoren von nav1.3 nav1.7
MX365525B (es) * 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
EP2809656A2 (de) 2011-12-28 2014-12-10 Allergan, Inc. Benzimidazolderivate als selektive blocker eines dauerhaften natriumstroms
EP2797896A1 (de) 2011-12-28 2014-11-05 Allergan, Inc. Benzimidazolderivate als selektive blocker eines dauerhaften natriumstroms
WO2014110628A1 (en) * 2013-01-18 2014-07-24 Itek Ventures Pty Ltd Gene and mutations thereof associated with seizure disorders
EP2770325A1 (de) 2013-02-26 2014-08-27 Institut du Cerveau et de la Moelle Epiniere-ICM Mutationen von DEPDC5 zur Diagnose von epileptischen Funktionsstörungen, Erkrankungen oder Leiden
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10813357B1 (en) 2015-05-26 2020-10-27 Gojo Industries, Inc. Compositions and methods with efficacy against spores and other organisms
TW202315946A (zh) 2017-04-03 2023-04-16 美商編碼製藥公司 組織選擇性轉基因表現
CA3085576A1 (en) 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
WO2019224864A1 (ja) * 2018-05-21 2019-11-28 国立研究開発法人理化学研究所 Ｓｃｎ１ａ遺伝子の発現増強法とそれによるドラベ症候群の治療法
US20230272387A1 (en) * 2020-07-22 2023-08-31 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5482845A (en) 1993-09-24 1996-01-09 The Trustees Of Columbia University In The City Of New York Method for construction of normalized cDNA libraries
US5593862A (en) * 1994-10-04 1997-01-14 Research Foundation Of State University Of New York Nucleic acids encoding drosophila tipE cation channel proteins and recombinant expression of the same
DE69535830D1 (de) 1994-11-02 2008-10-16 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
GB9513180D0 (en) * 1995-06-28 1995-08-30 Univ London Ion channel
US6030810A (en) * 1997-02-26 2000-02-29 Delgado; Stephen Gregory Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof
CA2307316C (en) * 1997-10-24 2010-12-21 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
US6269350B1 (en) * 1998-07-24 2001-07-31 Neopost Inc. Method and apparatus for placing automated service calls for postage meter and base
CA2394229C (en) 1999-11-26 2010-04-13 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US20020076780A1 (en) 2000-08-16 2002-06-20 Turner C. Alexander Novel human ion channel proteins and polynucleotides encoding the same
US6673549B1 (en) 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
AUPR220300A0 (en) * 2000-12-20 2001-01-25 Bionomics Limited New epilepsy gene

Also Published As

Publication number Publication date
EP2112234A3 (de) 2010-06-16
WO2001038564A3 (en) 2001-11-08
AU1846501A (en) 2001-06-04
EP2112234A2 (de) 2009-10-28
AU2014203437B2 (en) 2016-11-17
AU2007201991A1 (en) 2007-06-14
JP2007185199A (ja) 2007-07-26
JP4048053B2 (ja) 2008-02-13
CA2394229A1 (en) 2001-05-31
WO2001038564A2 (en) 2001-05-31
US7951931B2 (en) 2011-05-31
JP2004512812A (ja) 2004-04-30
AU2011201761A1 (en) 2011-05-12
US8143005B2 (en) 2012-03-27
US20090148855A1 (en) 2009-06-11
US7528093B2 (en) 2009-05-05
US20040096886A1 (en) 2004-05-20
CA2394229C (en) 2010-04-13
US20040096885A1 (en) 2004-05-20
US20040214195A1 (en) 2004-10-28
US7655460B2 (en) 2010-02-02
US20100092990A1 (en) 2010-04-15
AU2007201976A1 (en) 2007-06-21
EP1252330A2 (de) 2002-10-30
AU2014203437A1 (en) 2014-08-07
AU2007201976B2 (en) 2011-09-29
US7485449B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
DE1252330T1 (de) Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
DE69928237D1 (de) Verfahren zur behandlung von abwasser zur entfernung von organischen stoffen und stickstoff,
DE60024306D1 (de) Verfahren zur behandlung von radioaktivem graphit
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE59900581D1 (de) D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung
ATE230617T1 (de) Verfahren und methode zur behandlung von abfällen
DE60044718D1 (de) Mehrfrequenz-multipol und verfahren zu seiner verwendung
DE60044848D1 (de) Verfahren und Vorrichtung zur Unterdrückung der Anfrage für eine Rufinitialisierung
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE60035176D1 (de) System und verfahren zum überwachten herunterladen von rundfunkdaten
ATE249326T1 (de) Kontinuierliches verfahren zur trocknung und nachkondensation von granulat, anlage zur durchführung des verfahrens, und verwendung der anlage und des verfahrens
DE69916400D1 (de) Verfahren zur selektiven Entfernung von Nitrilen
DE69928534D1 (de) Verfahren zur behandlung flüssiger ströme
DE69511393D1 (de) Polymerzusammensetzung und verfahren zur behandlung von metalloberflächen
DE69905616T2 (de) Verfahren und zusammensetzung zur behandlung und vorbeugung von mycobacterium infektionen
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
DE60035326D1 (de) Verfahren zur Behandlung von Abwasser
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE60036899D1 (de) Chemikalie und verfahren zur wasserbehandlung
DE60027003D1 (de) Bakterielles konsortium ebc1000 und verfahren zu dessen verwendung zur behandlung von biologisch schwer abbaubaren toxischen chemikalien in industriellem abwasser, abfällen und böden
DE50311222D1 (de) Verfahren und system zum blockieren von unerwünschten nachrichten
DE59912246D1 (de) Ferroelektrischer transistor und verfahren zu dessen herstellung
DE69700952T2 (de) Zusammensetzungen für bodenbehandlung, verfahren zu deren herstellung und verwendung